N S Shah1,2, J Westenhouse2, P Lowenthal2, G Schecter2,3, L True2, S Mase1, P M Barry2, J Flood2. 1. Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STI and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. California Department of Public Health, Tuberculosis Control Branch, Richmond, California, USA. 3. University of California, San Francisco, California, USA.
Abstract
Background: The US Centers for Disease Control and Prevention recommend expert consultation for multi-drug-resistant tuberculosis (MDR-TB) cases. In 2002, the California MDR-TB Service was created to provide expert MDR-TB consultations. We describe the characteristics, treatment outcomes and management of patients referred to the Service. Methods: Surveillance data were used for descriptive analysis of cases, with consultation during July 2002-December 2012. Clinical consultation data and modified World Health Organization indicators were used to assess the care and management of cases, with consultation from January 2009 to December 2012. Results: Of 339 MDR-TB patients, 140 received a consultation. The proportion of patients receiving a consultation increased from 12% in 2002 to 63% in 2012. There were 24 pre-extensively drug-resistant TB and 5 patients with extensively drug-resistant TB. The majority (n = 123, 88%) completed treatment, 5 (4%) died, 7 (5%) moved before treatment completion, 4 (3%) stopped treatment due to an adverse event and 1 (1%) had an unknown outcome. Indicator data showed that 86% underwent rapid molecular drug susceptibility testing, 98% received at least four drugs to which they had known or presumed susceptibility, and 93% culture converted within 6 months. Conclusions: Consultations with the MDR-TB Service increased over time. Results highlight successful treatment and indicator outcomes.
Background: The US Centers for Disease Control and Prevention recommend expert consultation for multi-drug-resistant tuberculosis (MDR-TB) cases. In 2002, the California MDR-TB Service was created to provide expert MDR-TB consultations. We describe the characteristics, treatment outcomes and management of patients referred to the Service. Methods: Surveillance data were used for descriptive analysis of cases, with consultation during July 2002-December 2012. Clinical consultation data and modified World Health Organization indicators were used to assess the care and management of cases, with consultation from January 2009 to December 2012. Results: Of 339 MDR-TBpatients, 140 received a consultation. The proportion of patients receiving a consultation increased from 12% in 2002 to 63% in 2012. There were 24 pre-extensively drug-resistant TB and 5 patients with extensively drug-resistant TB. The majority (n = 123, 88%) completed treatment, 5 (4%) died, 7 (5%) moved before treatment completion, 4 (3%) stopped treatment due to an adverse event and 1 (1%) had an unknown outcome. Indicator data showed that 86% underwent rapid molecular drug susceptibility testing, 98% received at least four drugs to which they had known or presumed susceptibility, and 93% culture converted within 6 months. Conclusions: Consultations with the MDR-TB Service increased over time. Results highlight successful treatment and indicator outcomes.
Authors: Lauren A Beste; Thomas J Glorioso; P Michael Ho; David H Au; Susan R Kirsh; Jeffrey Todd-Stenberg; Michael F Chang; Jason A Dominitz; Anna E Barón; David Ross Journal: Am J Med Date: 2016-12-18 Impact factor: 4.965
Authors: Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew Magee; Henry M Blumberg; Russell R Kempker Journal: Clin Infect Dis Date: 2014-08-04 Impact factor: 9.079
Authors: Evan W Orenstein; Sanjay Basu; N Sarita Shah; Jason R Andrews; Gerald H Friedland; Anthony P Moll; Neel R Gandhi; Alison P Galvani Journal: Lancet Infect Dis Date: 2009-03 Impact factor: 25.071
Authors: Neela D Goswami; Sundari Mase; David Griffith; Rajita Bhavaraju; Alfred Lardizabal; Michael Lauzardo; Lisa Chen; John Wilson; Courtney Chappelle; Connie A Haley Journal: Open Forum Infect Dis Date: 2019-04-04 Impact factor: 3.835
Authors: Annie Belanger; Sapna Bamrah Morris; Richard Brostrom; David Yost; Neela Goswami; Margaret Oxtoby; Marisa Moore; Janice Westenhouse; Pennan M Barry; Neha S Shah Journal: J Clin Tuberc Other Mycobact Dis Date: 2019-01-27
Authors: Shereen Katrak; Phil Lowenthal; Richard Shen; Lisa True; Leslie Henry; Pennan Barry Journal: J Clin Tuberc Other Mycobact Dis Date: 2021-01-10
Authors: Sundari R Mase; Ratima Samron; David Ashkin; Kenneth G Castro; Stephen Ryan; Barbara Seaworth; Lisa Chen; Alfred Lardizabal; Dawn Tuckey; Amera Khan; Drew L Posey; Courtney Chappelle; Zelalem Temesgen Journal: J Clin Tuberc Other Mycobact Dis Date: 2019-07-02